Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3^rd Annual Genomic Medicines and Rare Disease Day.

Details for the events are as follows:

H.C. Wainwright Gene Therapy and Gene Editing Conference
Presentation Date:		Wednesday, March 30, 2022
Presentation Time:		7:00 a.m. EDT
Webcast Link:		https://journey.ct.events/view/5be9c8c9-116d-4777-b0f7-afc3aa88fd82

A webcast of the presentation will be available for 90 days beginning at 7:00 a.m. on March 30. It will also be posted in the Investors section of the Krystal Biotech website.

Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day
Fireside Chat Date:		Thursday, March 31, 2022
Fireside Chat Time:		2-2:45 p.m. EDT
Webcast and Replay Link:		https://kvgo.com/guggenheim/krystal-biotech-inc-march-2022

A replay of the fireside chat will be available via a link on the Krystal Biotech website approximately 48 hours after the event and will be viewable for 1 year.

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACTS:

Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com

Media:
Tiffany Hamilton
Krystal Biotech
thamilton@krystalbio.com

Source: Krystal Biotech, Inc.